Ressources - Page 4 sur 18 - PULSENMORE

Communiqués de presse

Pulsenmore announces first commercial engagement with a leading U.S.-based medical center

OMER, Israel, Feb 2, 2026 /PRNewswire/ — Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a pioneer in home ultrasound technology, today announced a first commercial engagement with a medical center in the

Communiqués de presse

Pulsenmore strategic agreement with Clalit for at-home follicular monitoring

Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation Commercial agreement potentially valued at approximately $4.5 million over five years following 18 month

Newsletters

January 2026 Newsletter

We’re excited to share a few key updates from Pulsenmore as we continue to expand our impact in maternal-fetal care. FDA authorization, and what it unlocks Receiving FDA De Novo

Actualités

We’re honored to have Prof. Alfred Abuhamad, a global leader in maternal-fetal medicine, on the Pulsenmore advisory board.

Pulsenmore introduces a transformative model for prenatal care - extending ultrasound access beyond the clinic and redefining how we reach and monitor expectant mothers.

Actualités, Communiqués de presse

FDA De Novo marketing authorization

RAMAT GAN, Israel, Nov. 3, 2025 /PRNewswire/ -- Pulsenmore Ltd. (TASE: PULS), a pioneer in home ultrasound solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted